Annual CFI
-$2.46 M
-$1.22 M-98.55%
31 December 2023
Summary:
Keros Therapeutics annual cash flow from investing activities is currently -$2.46 million, with the most recent change of -$1.22 million (-98.55%) on 31 December 2023. During the last 3 years, it has fallen by -$2.17 million (-738.10%). KROS annual CFI is now -1035.48% below its all-time high of -$217.00 thousand, reached on 31 December 2018.KROS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$386.00 K
-$76.00 K-24.52%
30 September 2024
Summary:
Keros Therapeutics quarterly cash flow from investing activities is currently -$386.00 thousand, with the most recent change of -$76.00 thousand (-24.52%) on 30 September 2024. Over the past year, it has increased by +$164.00 thousand (+29.82%).KROS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$2.18 M
+$164.00 K+6.99%
30 September 2024
Summary:
Keros Therapeutics TTM cash flow from investing activities is currently -$2.18 million, with the most recent change of +$164.00 thousand (+6.99%) on 30 September 2024. Over the past year, it has increased by +$91.00 thousand (+4.00%).KROS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KROS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -98.5% | +29.8% | +4.0% |
| 3 y3 years | -738.1% | -166.2% | -136.0% |
| 5 y5 years | -1035.5% | -370.7% | -762.9% |
KROS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -738.1% | at low | -166.2% | +63.6% | -136.0% | +11.4% |
| 5 y | 5 years | -1035.5% | at low | -2044.4% | +63.6% | -766.3% | +11.4% |
| alltime | all time | -1035.5% | at low | <-9999.0% | +63.6% | <-9999.0% | +11.4% |
Keros Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$386.00 K(+24.5%) | -$2.18 M(-7.0%) |
| June 2024 | - | -$310.00 K(-67.2%) | -$2.35 M(-0.0%) |
| Mar 2024 | - | -$946.00 K(+74.9%) | -$2.35 M(-4.7%) |
| Dec 2023 | -$2.46 M(+98.5%) | -$541.00 K(-1.6%) | -$2.46 M(+8.4%) |
| Sept 2023 | - | -$550.00 K(+76.8%) | -$2.27 M(+19.7%) |
| June 2023 | - | -$311.00 K(-70.7%) | -$1.90 M(-11.9%) |
| Mar 2023 | - | -$1.06 M(+202.6%) | -$2.16 M(+73.7%) |
| Dec 2022 | -$1.24 M(+21.2%) | -$351.00 K(+99.4%) | -$1.24 M(+18.3%) |
| Sept 2022 | - | -$176.00 K(-69.0%) | -$1.05 M(+3.0%) |
| June 2022 | - | -$567.00 K(+285.7%) | -$1.02 M(+5.9%) |
| Mar 2022 | - | -$147.00 K(-7.5%) | -$961.00 K(-6.2%) |
| Dec 2021 | -$1.02 M | -$159.00 K(+9.7%) | -$1.02 M(+10.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$145.00 K(-71.6%) | -$925.00 K(+14.2%) |
| June 2021 | - | -$510.00 K(+142.9%) | -$810.00 K(+147.0%) |
| Mar 2021 | - | -$210.00 K(+250.0%) | -$328.00 K(+11.6%) |
| Dec 2020 | -$294.00 K(+8.5%) | -$60.00 K(+100.0%) | -$294.00 K(+16.7%) |
| Sept 2020 | - | -$30.00 K(+7.1%) | -$252.00 K(-17.1%) |
| June 2020 | - | -$28.00 K(-84.1%) | -$304.00 K(-32.0%) |
| Mar 2020 | - | -$176.00 K(+877.8%) | -$447.00 K(+64.9%) |
| Dec 2019 | -$271.00 K(+24.9%) | -$18.00 K(-78.0%) | -$271.00 K(+7.1%) |
| Sept 2019 | - | -$82.00 K(-52.0%) | -$253.00 K(+48.0%) |
| June 2019 | - | -$171.00 K(<-9900.0%) | -$171.00 K(<-9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | -$217.00 K | - | - |
FAQ
- What is Keros Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Keros Therapeutics?
- What is Keros Therapeutics annual CFI year-on-year change?
- What is Keros Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Keros Therapeutics?
- What is Keros Therapeutics quarterly CFI year-on-year change?
- What is Keros Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Keros Therapeutics?
- What is Keros Therapeutics TTM CFI year-on-year change?
What is Keros Therapeutics annual cash flow from investing activities?
The current annual CFI of KROS is -$2.46 M
What is the all time high annual CFI for Keros Therapeutics?
Keros Therapeutics all-time high annual cash flow from investing activities is -$217.00 K
What is Keros Therapeutics annual CFI year-on-year change?
Over the past year, KROS annual cash flow from investing activities has changed by -$1.22 M (-98.55%)
What is Keros Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of KROS is -$386.00 K
What is the all time high quarterly CFI for Keros Therapeutics?
Keros Therapeutics all-time high quarterly cash flow from investing activities is $0.00
What is Keros Therapeutics quarterly CFI year-on-year change?
Over the past year, KROS quarterly cash flow from investing activities has changed by +$164.00 K (+29.82%)
What is Keros Therapeutics TTM cash flow from investing activities?
The current TTM CFI of KROS is -$2.18 M
What is the all time high TTM CFI for Keros Therapeutics?
Keros Therapeutics all-time high TTM cash flow from investing activities is $0.00
What is Keros Therapeutics TTM CFI year-on-year change?
Over the past year, KROS TTM cash flow from investing activities has changed by +$91.00 K (+4.00%)